GlassScriptPhysician profile
Shine Vazhappilly
NPI 1790351781
$5,750.60
in general payments reported to CMS, 2019-2025
19 companies · $3,857 in 2025
The $3,857 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2024: $1,781 · 2025: $3,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,538 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,537.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,186.09 | 2024-2025 | |
| Abbvie INC. | $1,128.17 | 2024-2025 | |
| Amgen INC. | $819.77 | 2024-2025 | Evenity, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $625.64 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $393.34 | 2024-2025 | Tezspire, Saphnelo |
| Janssen Biotech, INC. | $283.80 | 2024-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.85 | 2024-2025 | Jardiance, Spevigo |
| Ucb, INC. | $238.62 | 2024-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $148.79 | 2024-2025 | Tymlos |
| Sobi, INC | $138.90 | 2024-2025 | |
| Celgene Corporation | $134.19 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.00 | 2022 | |
| Lilly USA, LLC | $69.42 | 2025 | Taltz, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $43.07 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $39.79 | 2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $32.61 | 2025 | |
| Inari Medical, INC. | $24.70 | 2022 | |
| Genentech USA, INC. | $13.86 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shine Vazhappilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.